Update to ASCO/CAP Guideline in Breast Cancer: No Sweeping Changes, but Many Refinements - Cancer Therapy Advisor
![PDF] HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical](https://d3i71xaburhd42.cloudfront.net/c7289407931d6ff274350f21b4024900edadc66e/2-Figure1-1.png "PDF] HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical")
PDF] HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/ CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer | Virchows Archiv
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows | BMC Medical Genomics | Full Text
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows | BMC Medical Genomics | Full Text
Q&A column - CAP TODAY
HER2 spectrum of expression according to ASCO/CAP guidelines. HER2-low... | Download Scientific Diagram
Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer
Second act for HER2, in gastric cancers - CAP TODAY
ASCO/CAP immunohistochemical HER2 evaluation protocol (2007) | Download Table
ASCO/CAP Guidelines To Determine ER Status May Need Rehaul - General Surgery News
![PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b66331181b2eafa14b6e478dcc7fced0c7917993/3-Table1-1.png "PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar")
PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar
Le linee guida ASCO/CAP 2018
PPT - HER2 Testing in Breast Cancer: 2013 ASCO/CAP HER2 Guideline Update PowerPoint Presentation - ID:6109259
Brittany Harvey on X: "Listen to the latest @ASCO Guidelines podcast episode to hear co-chairs @awolff and @DrKimAllison discuss this ASCO-CAP HER2 testing guideline update with me, including the implications for clinicians
Updated (2018) ASCO/CAP Guidelines for HER2 Testing in Breast Cancer - Insights
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology
ASCO 2020: HER2 Reclassification - Agendia Inc.
ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia - ScienceDirect
Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents - Modern Pathology
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/ CAP ISH group 4 breast cancer | npj Breast Cancer
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update | Journal of Clinical Oncology
CACSV
